Sanofi Halts Multaq Trial Early Due To Cardiac Events
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.